CBL Antikörper (pTyr731) (FITC)

Produktnummer ABIN683975

Der Kaninchen Polyklonal Anti-CBL-Antikörper wurde für IF (p) und IF (cc) validiert. Er ist geeignet, CBL in Proben von Human zu detektieren.

Kurzübersicht für CBL Antikörper (pTyr731) (FITC) (ABIN683975)

Target: CBL (Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence (CBL))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CBL Antikörper ist konjugiert mit FITC

Applikation: Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunofluorescence (Cultured Cells) (IF (cc))

Produktdetails anti-CBL Antikörper (FITC)

Bindungsspezifität: pTyr731

Homologie: Human,Mouse,Rat,Dog,Cow,Pig

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic phosphopeptide derived from human CBL2 around the phosphorylation site of Tyr731

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Haltbarkeit: 12 months

Details zu CBL

Target: CBL (Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence (CBL))

Andere Bezeichnung: CBL2

Hintergrund:

Synonyms: C CBL Tyr731, CBL2 Tyr731, CBL2 Tyr731, p-CBL2 Tyr731, p-CBL2 Y731, C CBL, Cas-Br-M murine ecotropic retroviral transforming sequence, Casitas B lineage lymphoma proto oncogene, CBL 2,E3 ubiquitin protein ligase CBL, Oncogene CBL2, Proto oncogene c CBL, RGD1561386, RING finger protein 55, RNF55v Signal transduction protein CBL, 4732447J05Rik, CBL_HUMAN.

Background: The proto oncogene c CBL was initially identified as the cellular homologue of v CBL oncogene that induces pre B cell lymphomas and myeloid leukemias in mice. In more recent studies CBL has been shown to be a negative regulator of tyrosine kinase signaling. The ubiquitin ligase activity of CBL leads to the degradation of tyrosine kinases, thus attenuating the signal of receptors. Targets of CBL include activated protein tyrosine kinases belonging to the Src and Syk/Zap 70 families. An additional mechanism to attenuate receptor signaling is thought to be achieved by CBL?s interaction with downstream targets of tyrosine kinases, such as PI 3K and Vav.

Gen-ID: 867

Pathways: T-Zell Rezeptor Signalweg, Interferon-gamma Pathway, EGFR Signaling Pathway, EGFR Downregulation, VEGFR1 Specific Signals